Longeveron Inc. Common Stock (LGVN) is a publicly traded Healthcare sector company. As of October 26, 2026, LGVN trades at $1.69 with a market cap of $5.10M and a P/E ratio of -0.91. LGVN moved +10.31% today. Year to date, LGVN is -68.38%; over the trailing twelve months it is -81.18%. Its 52-week range spans $1.31 to $19.20. Analyst consensus is buy with an average price target of $30.00. Rallies surfaces LGVN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Longeveron’s laromestrocel shows fewer major adverse cardiac events in Phase 2b trial: Longeveron reported that laromestrocel significantly reduced major adverse cardiac events in infants with hypoplastic left heart syndrome in updated ELPIS II Phase 2b results. The trial had previously failed its primary goal of improving right ventricular pumping function at 12 months.
| Metric | Value |
|---|---|
| Price | $1.69 |
| Market Cap | $5.10M |
| P/E Ratio | -0.91 |
| EPS | $-2.62 |
| Dividend Yield | 0.00% |
| 52-Week High | $19.20 |
| 52-Week Low | $1.31 |
| Volume | 77.00K |
| Avg Volume | 0 |
| Revenue (TTM) | $2.39M |
| Net Income | $-15.97M |
| Gross Margin | 78.76% |
2 analysts cover LGVN: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $30.00.